Showing results (221-230 of 264) with videos related to

Sort By:
Pageof 27
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 16, 2021
Single-Agent Mosunetuzumab Shows Durable Complete Responses in Patients With Relapsed or Refractory B-Cell Lymphomas: Phase I Dose-Escalation StudyLihua E Budde, Sarit Assouline, Laurie H Sehn, et al.
Blood Research|October 19, 2017
Platelet to lymphocyte ratio (PLR) retains independent prognostic significance in advanced stage marginal zone lymphoma patients treated with rituximab, cyclophosphamide, vincristine, and prednisone combination chemotherapy (R-CVP): Consortium for Improving Survival of Lymphoma trialJeongkuk Seo, Won Seog Kim, Jin Seok Kim, et al.
Neuro-Oncology|December 3, 2025
A Novel Prognostic Model for Primary CNS Lymphoma Incorporating Clinico-Laboratory ParametersYeokyeong Shin, Jaewon Hyung, Shin Kim, et al.
Leukemia & Lymphoma|September 29, 2015
A phase II study of oxaliplatin and prednisone for patients with relapsed or refractory marginal zone lymphoma: Consortium for Improving Survival of Lymphoma trialSung Yong Oh, Won Seog Kim, Jin Seok Kim, et al.
Annals of Hematology|January 17, 2024
Immune profiling of patients with extranodal natural killer/T cell lymphoma treated with daratumumabMin Qing, Tianyuan Zhou, Tatiana Perova, et al.
Blood Research|November 21, 2021
Multicenter retrospective analysis of patients with chronic lymphocytic leukemia in KoreaJun Ho Yi, Gyeong-Won Lee, Ji Hyun Lee, et al.
Annals of Hematology|July 27, 2011
Clinical features and outcomes of Hodgkin's lymphoma in Korea: Consortium for Improving Survival of Lymphoma (CISL)Young-Woong Won, Jung Hye Kwon, Soon Il Lee, et al.
Biomed Research International|July 5, 2014
Clinical factors associated with response or survival after chemotherapy in patients with Waldenström macroglobulinemia in KoreaHo Sup Lee, Kihyun Kim, Dok Hyun Yoon, et al.
Blood Advances|April 17, 2023
Mosunetuzumab monotherapy is active and tolerable in patients with relapsed/refractory diffuse large B-cell lymphomaNancy L Bartlett, Sarit Assouline, Pratyush Giri, et al.
Annals of Hematology|January 4, 2020
A phase II study of etoposide, methylprednisolone, high-dose cytarabine, and oxaliplatin (ESHAOx) for patients with refractory or relapsed Hodgkin's lymphomaYoung-Woong Won, Hyewon Lee, Hyeon-Seok Eom, et al.
Pageof 27